HLA-B51 and its main subtypes in Brazilian patients with Behçet's disease
This study aimed to evaluate the frequency of HLA-B*51 and its subtypes in Brazilian patients with Behçet's disease (BD) and healthy controls (HC) and to assess possible associations with disease manifestations. A cross-sectional study with sequential BD patients and HC. HLAB*51 presence was de...
Gespeichert in:
| Veröffentlicht in: | Clinical and experimental rheumatology 2020-09, Vol.38 Suppl 127 (5), p.53-59 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 59 |
|---|---|
| container_issue | 5 |
| container_start_page | 53 |
| container_title | Clinical and experimental rheumatology |
| container_volume | 38 Suppl 127 |
| creator | Belem, Joice Moraes F M Fraga, Ana Maria Andrade, Luis Eduardo Coelho de Souza, Alexandre W S |
| description | This study aimed to evaluate the frequency of HLA-B*51 and its subtypes in Brazilian patients with Behçet's disease (BD) and healthy controls (HC) and to assess possible associations with disease manifestations.
A cross-sectional study with sequential BD patients and HC. HLAB*51 presence was determined by sequence-specific polymerase chain reaction (SSP-PCR) and HLA-B*51 subtypes by the Sanger sequencing method.
Eighty-three BD patients and 258 HC were evaluated. HLA-B*51 was found in 30.1% of DB patients and in 15.5% of HC (p=0.003). The most prevalent subtypes in DB patients were HLA-B*51:01 (60.0%), HLA-B*51:08 (20.0%), HLA-B*51:22 (8.0%), HLAB* 51:29 (8.0%) and HLA-B*51:02 (4.0%), while HLA-B*51:01 (77.5%) and HLA-B*51:55 (7.5%) were the most prevalent in HC. HLA-B*51 was less frequently found in patients with neurologic involvement (8.0% vs. 29.3%; p=0.034) while HLAB*51:01 was more observed in patients with ocular involvement (93.3% vs. 60.3%; p=0.014). No BD patient with neurologic or vascular involvement presented HLA-B*51:01. HLAB*51:08 was more frequent in patients with vascular manifestations (60.0% vs. 15.4%; p=0.012). In multivariate analysis, HLA-B*51 was an independent risk factor for BD (OR=2.410; 95%CI: 1.332-4.361; p=0.004) and HLA-B*51:08 had an independent association with vascular manifestations of BD (OR = 14.843; 95%CI: 1.550 - 142.115; p=0.019).
The prevalence of HLAB*51 is higher in Brazilian BD patients compared to HC, and it is a risk factor for BD. The HLA-B*51:08 subtype was independently associated with vascular manifestations of BD. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_2456419739</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2456419739</sourcerecordid><originalsourceid>FETCH-LOGICAL-p211t-69d7b9acbc1886cdeace01bc43c5846c9f4cb51bacc98e52b4f8f1ab27e709703</originalsourceid><addsrcrecordid>eNo1j8FKxDAURbNQnHH0FyQ73RSapEma5XRQRym4UXBXXtJXJtJ2apMi4w_5If7YFBxX9y4OB84ZWabC8CSX6n1BLkP4SFOupNIXZCEE45nUfEmet-U6KSSj0NfUx0A78D0Nk42HAQOdfzHCt2899HSA6LGfmS8fd7TA3e8PxttAax8QAl6R8wbagNenXZG3h_vXzTYpXx6fNusyGThjMVGm1taAs47luXI1gsOUWZcJJ_NMOdNkzkpmwTmTo-Q2a_KGgeUadWp0Klbk7s87jPvPCUOsOh8cti30uJ9CNZepjBktzIzenNDJdlhXw-g7GA_Vf784Au5nVis</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2456419739</pqid></control><display><type>article</type><title>HLA-B51 and its main subtypes in Brazilian patients with Behçet's disease</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Belem, Joice Moraes F M ; Fraga, Ana Maria ; Andrade, Luis Eduardo Coelho ; de Souza, Alexandre W S</creator><creatorcontrib>Belem, Joice Moraes F M ; Fraga, Ana Maria ; Andrade, Luis Eduardo Coelho ; de Souza, Alexandre W S</creatorcontrib><description>This study aimed to evaluate the frequency of HLA-B*51 and its subtypes in Brazilian patients with Behçet's disease (BD) and healthy controls (HC) and to assess possible associations with disease manifestations.
A cross-sectional study with sequential BD patients and HC. HLAB*51 presence was determined by sequence-specific polymerase chain reaction (SSP-PCR) and HLA-B*51 subtypes by the Sanger sequencing method.
Eighty-three BD patients and 258 HC were evaluated. HLA-B*51 was found in 30.1% of DB patients and in 15.5% of HC (p=0.003). The most prevalent subtypes in DB patients were HLA-B*51:01 (60.0%), HLA-B*51:08 (20.0%), HLA-B*51:22 (8.0%), HLAB* 51:29 (8.0%) and HLA-B*51:02 (4.0%), while HLA-B*51:01 (77.5%) and HLA-B*51:55 (7.5%) were the most prevalent in HC. HLA-B*51 was less frequently found in patients with neurologic involvement (8.0% vs. 29.3%; p=0.034) while HLAB*51:01 was more observed in patients with ocular involvement (93.3% vs. 60.3%; p=0.014). No BD patient with neurologic or vascular involvement presented HLA-B*51:01. HLAB*51:08 was more frequent in patients with vascular manifestations (60.0% vs. 15.4%; p=0.012). In multivariate analysis, HLA-B*51 was an independent risk factor for BD (OR=2.410; 95%CI: 1.332-4.361; p=0.004) and HLA-B*51:08 had an independent association with vascular manifestations of BD (OR = 14.843; 95%CI: 1.550 - 142.115; p=0.019).
The prevalence of HLAB*51 is higher in Brazilian BD patients compared to HC, and it is a risk factor for BD. The HLA-B*51:08 subtype was independently associated with vascular manifestations of BD.</description><identifier>ISSN: 0392-856X</identifier><identifier>PMID: 33124572</identifier><language>eng</language><publisher>Italy</publisher><subject>Behcet Syndrome - diagnosis ; Behcet Syndrome - epidemiology ; Behcet Syndrome - genetics ; Brazil ; Cross-Sectional Studies ; HLA-B Antigens - genetics ; HLA-B51 Antigen - genetics ; Humans</subject><ispartof>Clinical and experimental rheumatology, 2020-09, Vol.38 Suppl 127 (5), p.53-59</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33124572$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Belem, Joice Moraes F M</creatorcontrib><creatorcontrib>Fraga, Ana Maria</creatorcontrib><creatorcontrib>Andrade, Luis Eduardo Coelho</creatorcontrib><creatorcontrib>de Souza, Alexandre W S</creatorcontrib><title>HLA-B51 and its main subtypes in Brazilian patients with Behçet's disease</title><title>Clinical and experimental rheumatology</title><addtitle>Clin Exp Rheumatol</addtitle><description>This study aimed to evaluate the frequency of HLA-B*51 and its subtypes in Brazilian patients with Behçet's disease (BD) and healthy controls (HC) and to assess possible associations with disease manifestations.
A cross-sectional study with sequential BD patients and HC. HLAB*51 presence was determined by sequence-specific polymerase chain reaction (SSP-PCR) and HLA-B*51 subtypes by the Sanger sequencing method.
Eighty-three BD patients and 258 HC were evaluated. HLA-B*51 was found in 30.1% of DB patients and in 15.5% of HC (p=0.003). The most prevalent subtypes in DB patients were HLA-B*51:01 (60.0%), HLA-B*51:08 (20.0%), HLA-B*51:22 (8.0%), HLAB* 51:29 (8.0%) and HLA-B*51:02 (4.0%), while HLA-B*51:01 (77.5%) and HLA-B*51:55 (7.5%) were the most prevalent in HC. HLA-B*51 was less frequently found in patients with neurologic involvement (8.0% vs. 29.3%; p=0.034) while HLAB*51:01 was more observed in patients with ocular involvement (93.3% vs. 60.3%; p=0.014). No BD patient with neurologic or vascular involvement presented HLA-B*51:01. HLAB*51:08 was more frequent in patients with vascular manifestations (60.0% vs. 15.4%; p=0.012). In multivariate analysis, HLA-B*51 was an independent risk factor for BD (OR=2.410; 95%CI: 1.332-4.361; p=0.004) and HLA-B*51:08 had an independent association with vascular manifestations of BD (OR = 14.843; 95%CI: 1.550 - 142.115; p=0.019).
The prevalence of HLAB*51 is higher in Brazilian BD patients compared to HC, and it is a risk factor for BD. The HLA-B*51:08 subtype was independently associated with vascular manifestations of BD.</description><subject>Behcet Syndrome - diagnosis</subject><subject>Behcet Syndrome - epidemiology</subject><subject>Behcet Syndrome - genetics</subject><subject>Brazil</subject><subject>Cross-Sectional Studies</subject><subject>HLA-B Antigens - genetics</subject><subject>HLA-B51 Antigen - genetics</subject><subject>Humans</subject><issn>0392-856X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1j8FKxDAURbNQnHH0FyQ73RSapEma5XRQRym4UXBXXtJXJtJ2apMi4w_5If7YFBxX9y4OB84ZWabC8CSX6n1BLkP4SFOupNIXZCEE45nUfEmet-U6KSSj0NfUx0A78D0Nk42HAQOdfzHCt2899HSA6LGfmS8fd7TA3e8PxttAax8QAl6R8wbagNenXZG3h_vXzTYpXx6fNusyGThjMVGm1taAs47luXI1gsOUWZcJJ_NMOdNkzkpmwTmTo-Q2a_KGgeUadWp0Klbk7s87jPvPCUOsOh8cti30uJ9CNZepjBktzIzenNDJdlhXw-g7GA_Vf784Au5nVis</recordid><startdate>20200901</startdate><enddate>20200901</enddate><creator>Belem, Joice Moraes F M</creator><creator>Fraga, Ana Maria</creator><creator>Andrade, Luis Eduardo Coelho</creator><creator>de Souza, Alexandre W S</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20200901</creationdate><title>HLA-B51 and its main subtypes in Brazilian patients with Behçet's disease</title><author>Belem, Joice Moraes F M ; Fraga, Ana Maria ; Andrade, Luis Eduardo Coelho ; de Souza, Alexandre W S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p211t-69d7b9acbc1886cdeace01bc43c5846c9f4cb51bacc98e52b4f8f1ab27e709703</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Behcet Syndrome - diagnosis</topic><topic>Behcet Syndrome - epidemiology</topic><topic>Behcet Syndrome - genetics</topic><topic>Brazil</topic><topic>Cross-Sectional Studies</topic><topic>HLA-B Antigens - genetics</topic><topic>HLA-B51 Antigen - genetics</topic><topic>Humans</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Belem, Joice Moraes F M</creatorcontrib><creatorcontrib>Fraga, Ana Maria</creatorcontrib><creatorcontrib>Andrade, Luis Eduardo Coelho</creatorcontrib><creatorcontrib>de Souza, Alexandre W S</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and experimental rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Belem, Joice Moraes F M</au><au>Fraga, Ana Maria</au><au>Andrade, Luis Eduardo Coelho</au><au>de Souza, Alexandre W S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>HLA-B51 and its main subtypes in Brazilian patients with Behçet's disease</atitle><jtitle>Clinical and experimental rheumatology</jtitle><addtitle>Clin Exp Rheumatol</addtitle><date>2020-09-01</date><risdate>2020</risdate><volume>38 Suppl 127</volume><issue>5</issue><spage>53</spage><epage>59</epage><pages>53-59</pages><issn>0392-856X</issn><abstract>This study aimed to evaluate the frequency of HLA-B*51 and its subtypes in Brazilian patients with Behçet's disease (BD) and healthy controls (HC) and to assess possible associations with disease manifestations.
A cross-sectional study with sequential BD patients and HC. HLAB*51 presence was determined by sequence-specific polymerase chain reaction (SSP-PCR) and HLA-B*51 subtypes by the Sanger sequencing method.
Eighty-three BD patients and 258 HC were evaluated. HLA-B*51 was found in 30.1% of DB patients and in 15.5% of HC (p=0.003). The most prevalent subtypes in DB patients were HLA-B*51:01 (60.0%), HLA-B*51:08 (20.0%), HLA-B*51:22 (8.0%), HLAB* 51:29 (8.0%) and HLA-B*51:02 (4.0%), while HLA-B*51:01 (77.5%) and HLA-B*51:55 (7.5%) were the most prevalent in HC. HLA-B*51 was less frequently found in patients with neurologic involvement (8.0% vs. 29.3%; p=0.034) while HLAB*51:01 was more observed in patients with ocular involvement (93.3% vs. 60.3%; p=0.014). No BD patient with neurologic or vascular involvement presented HLA-B*51:01. HLAB*51:08 was more frequent in patients with vascular manifestations (60.0% vs. 15.4%; p=0.012). In multivariate analysis, HLA-B*51 was an independent risk factor for BD (OR=2.410; 95%CI: 1.332-4.361; p=0.004) and HLA-B*51:08 had an independent association with vascular manifestations of BD (OR = 14.843; 95%CI: 1.550 - 142.115; p=0.019).
The prevalence of HLAB*51 is higher in Brazilian BD patients compared to HC, and it is a risk factor for BD. The HLA-B*51:08 subtype was independently associated with vascular manifestations of BD.</abstract><cop>Italy</cop><pmid>33124572</pmid><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0392-856X |
| ispartof | Clinical and experimental rheumatology, 2020-09, Vol.38 Suppl 127 (5), p.53-59 |
| issn | 0392-856X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2456419739 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Behcet Syndrome - diagnosis Behcet Syndrome - epidemiology Behcet Syndrome - genetics Brazil Cross-Sectional Studies HLA-B Antigens - genetics HLA-B51 Antigen - genetics Humans |
| title | HLA-B51 and its main subtypes in Brazilian patients with Behçet's disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T19%3A31%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=HLA-B51%20and%20its%20main%20subtypes%20in%20Brazilian%20patients%20with%20Beh%C3%A7et's%20disease&rft.jtitle=Clinical%20and%20experimental%20rheumatology&rft.au=Belem,%20Joice%20Moraes%20F%20M&rft.date=2020-09-01&rft.volume=38%20Suppl%20127&rft.issue=5&rft.spage=53&rft.epage=59&rft.pages=53-59&rft.issn=0392-856X&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E2456419739%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2456419739&rft_id=info:pmid/33124572&rfr_iscdi=true |